Agenus Inc (AGEN)

$4.15 +0.01 (0.24%)
Market Cap 131.92M
Revenue (ttm) 103.46M
Net Income (ttm) -227.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 6.51
Profit Margin -219.61%
Debt to Equity Ratio -0.10
Volume 406,000
Avg Vol 501,010
Day's Range N/A - N/A
Shares Out 31.86M
Stochastic %K 51%
Beta 1.43
Analysts Sell
Price Target $12.33

Company Profile

Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 674 4400
Fax: 781 674 4200
Address:
3 Forbes Road, Lexington, United States
Biotechguy21
Biotechguy21 Oct. 6 at 11:29 PM
$AGEN checking in. anyone go to jail yet? 😂😂🤡🤡
0 · Reply
BOUDIN420
BOUDIN420 Oct. 6 at 5:06 PM
$AGEN
0 · Reply
meb2710
meb2710 Oct. 6 at 4:34 PM
$AGEN https://www.nature.com/articles/s41573-024-01089-x
0 · Reply
2_logs_higher
2_logs_higher Oct. 6 at 2:09 AM
$AGEN What does Takeda (Japanese) know that Zydus (Indian) or Agenus (USA) doesn't? More layoffs. Agen should have had more RIFS by NOW. https://www.bostonglobe.com/2025/10/04/business/takeda-layoffs-massachusetts-biopharma/
0 · Reply
2_logs_higher
2_logs_higher Oct. 6 at 1:45 AM
$AGEN Good for Agen? https://www.linkedin.com/posts/ndevitomd_tcl-chris-biggar-and-the-importance-of-nci-activity-7380577295666712576-lnae?utm_medium=ios_app&rcm=ACoAAEHAee4BR-loExEE38VAh_pzlu_m6nyixzY&utm_source=social_share_send&utm_campaign=mail
1 · Reply
joechuck71
joechuck71 Oct. 6 at 12:40 AM
$AGEN Botensilimab + Balstilimab vs Best Supportive Care has moved into phase 3 on the agenus page.
0 · Reply
2_logs_higher
2_logs_higher Oct. 5 at 12:40 AM
$AGEN Doors closing on other opportunities for Agen as they sit in the shoulder of the road broken down waiting on THE ROAD TAKEN An FDA approval is setting a new benchmark for future treatment for first-line small cell lung cancer. The FDA has greenlighted Jazz Pharmaceuticals’ Zepzelca, used in combination with Roche’s Tecentriq, as a first-line maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC), the agency said Thursday. The approval also applies to Tecentriq Hybreza, a subcutaneous version of the Roche PD-L1 inhibitor. https://www.fiercepharma.com/pharma/fda-approval-jazz-and-roche-combo-sets-new-bar-first-line-small-cell-lung-cancer G will come out with a teaser in 2-4 months with 1 patient or mice and say BOT + BAL + a dab of QS-21 is SIGNIFICANTLY superior, no PR, no Wed meeting.
2 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 4 at 9:47 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $AGEN Current Share Price: $4.14 Contracts: $AGEN January 15, 2027 $5 Calls Scale in: $1.06- $1.29 Scale out: $1.64-$2.11 Can Easily Capture: 60% ROI Blended DTE: 469 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
robbiekuss1
robbiekuss1 Oct. 4 at 8:37 PM
$AGEN Is the SaponiQX output considered a generic? SaponiQx, a subsidiary of Agenus, develops and manufactures its saponin-based adjuvants using a proprietary cultured plant cell (cpc) technology. While the headquarters for SaponiQx (and its parent company, Agenus) is in Lexington, Massachusetts, the specific location of its manufacturing is related to Agenus's broader manufacturing operations: Agenus's California Facilities: Agenus had cGMP (current Good Manufacturing Practice) facilities in Berkeley, CA (clinical scale) and Emeryville, CA (commercial scale).
2 · Reply
dikbukiss
dikbukiss Oct. 4 at 8:09 PM
$AGEN nice curl on the 1 month. 3 white soldiers pattern
2 · Reply
Latest News on AGEN
France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer

Sep 9, 2025, 7:43 AM EDT - 27 days ago

France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer

Agenus to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 8:52 AM EDT - 4 weeks ago

Agenus to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Agenus Inc. (AGEN) Virtual Stakeholder Briefing Call (Transcript)

Aug 28, 2025, 2:04 PM EDT - 5 weeks ago

Agenus Inc. (AGEN) Virtual Stakeholder Briefing Call (Transcript)

Update: Agenus Aug 27 Stakeholder Webcast—Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight

Aug 26, 2025, 9:37 AM EDT - 5 weeks ago

Update: Agenus Aug 27 Stakeholder Webcast—Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight

Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025

Aug 19, 2025, 7:30 AM EDT - 6 weeks ago

Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025

Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress

Aug 11, 2025, 7:30 AM EDT - 2 months ago

Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress

Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report

Jul 31, 2025, 7:30 AM EDT - 2 months ago

Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report

Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025

Jul 25, 2025, 12:46 PM EDT - 2 months ago

Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025

Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3

Jul 7, 2025, 8:55 AM EDT - 3 months ago

Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3

Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology

Jun 17, 2025, 7:30 AM EDT - 3 months ago

Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology

Agenus Announces Virtual Annual Shareholders Meeting

Jun 10, 2025, 1:30 PM EDT - 4 months ago

Agenus Announces Virtual Annual Shareholders Meeting

Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang

Jun 4, 2025, 2:38 PM EDT - 4 months ago

Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang

Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the US

Jun 3, 2025, 7:00 AM EDT - 4 months ago

Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the US

Agenus Presents New Data at ASCO Highlighting Botensilimab's Immune Activation in MSS Colorectal Cancer

May 30, 2025, 7:30 AM EDT - 4 months ago

Agenus Presents New Data at ASCO Highlighting Botensilimab's Immune Activation in MSS Colorectal Cancer

Agenus: Big On BOT/BAL As Cash Burn And Catalysts Collide

May 23, 2025, 3:09 PM EDT - 4 months ago

Agenus: Big On BOT/BAL As Cash Burn And Catalysts Collide

Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025

May 15, 2025, 10:40 AM EDT - 5 months ago

Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025

Agenus Inc. (AGEN) Q1 2025 Earnings Call Transcript

May 12, 2025, 2:46 PM EDT - 5 months ago

Agenus Inc. (AGEN) Q1 2025 Earnings Call Transcript

Agenus Reports Q1 2025 Financial Results and Key Business Updates

May 12, 2025, 7:30 AM EDT - 5 months ago

Agenus Reports Q1 2025 Financial Results and Key Business Updates

Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer

May 12, 2025, 7:20 AM EDT - 5 months ago

Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer

Agenus to Provide Corporate Update and First Quarter 2025 Financial Report

Apr 29, 2025, 7:30 AM EDT - 5 months ago

Agenus to Provide Corporate Update and First Quarter 2025 Financial Report

Agenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR

Apr 28, 2025, 3:30 PM EDT - 5 months ago

Agenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR

Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025

Apr 25, 2025, 1:05 PM EDT - 5 months ago

Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025

Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025

Apr 23, 2025, 12:05 PM EDT - 5 months ago

Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025

Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025

Mar 25, 2025, 4:40 PM EDT - 6 months ago

Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025

Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation

Mar 19, 2025, 7:30 AM EDT - 7 months ago

Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation

Agenus Inc. (AGEN) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 10:39 AM EDT - 7 months ago

Agenus Inc. (AGEN) Q4 2024 Earnings Call Transcript

Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program

Mar 11, 2025, 7:30 AM EDT - 7 months ago

Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program

Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications

Feb 26, 2025, 4:48 PM EST - 7 months ago

Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications

Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference

Feb 25, 2025, 2:30 PM EST - 7 months ago

Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference

Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Feb 25, 2025, 8:26 AM EST - 7 months ago

Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting

Feb 24, 2025, 8:33 AM EST - 8 months ago

Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting

CORRECTING and REPLACING Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

Feb 23, 2025, 7:38 PM EST - 8 months ago

CORRECTING and REPLACING Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

Feb 12, 2025, 1:00 PM EST - 8 months ago

Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Jan 29, 2025, 12:37 PM EST - 8 months ago

Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease

Jan 22, 2025, 2:48 PM EST - 9 months ago

Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease

Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers

Dec 18, 2024, 7:30 AM EST - 10 months ago

Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers

Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs

Dec 5, 2024, 7:30 AM EST - 10 months ago

Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs

Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment

Nov 27, 2024, 8:15 AM EST - 11 months ago

Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment

Agenus Inc. (AGEN) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 10:41 AM EST - 11 months ago

Agenus Inc. (AGEN) Q3 2024 Earnings Call Transcript

Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development

Nov 12, 2024, 7:00 AM EST - 11 months ago

Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development

Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024

Nov 7, 2024, 10:00 AM EST - 11 months ago

Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024

Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update

Nov 5, 2024, 7:30 AM EST - 11 months ago

Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update

November 5 Deadline: Agenus Inc Is Being Sued For Defrauding The Public And Affected Shareholders Are Urged To Contact The Schall Law Firm

Nov 4, 2024, 11:00 AM EST - 1 year ago

November 5 Deadline: Agenus Inc Is Being Sued For Defrauding The Public And Affected Shareholders Are Urged To Contact The Schall Law Firm

Agenus Inc Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Urged To Contact The Schall Law Firm

Nov 2, 2024, 11:00 AM EDT - 1 year ago

Agenus Inc Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Urged To Contact The Schall Law Firm

Biotechguy21
Biotechguy21 Oct. 6 at 11:29 PM
$AGEN checking in. anyone go to jail yet? 😂😂🤡🤡
0 · Reply
BOUDIN420
BOUDIN420 Oct. 6 at 5:06 PM
$AGEN
0 · Reply
meb2710
meb2710 Oct. 6 at 4:34 PM
$AGEN https://www.nature.com/articles/s41573-024-01089-x
0 · Reply
2_logs_higher
2_logs_higher Oct. 6 at 2:09 AM
$AGEN What does Takeda (Japanese) know that Zydus (Indian) or Agenus (USA) doesn't? More layoffs. Agen should have had more RIFS by NOW. https://www.bostonglobe.com/2025/10/04/business/takeda-layoffs-massachusetts-biopharma/
0 · Reply
2_logs_higher
2_logs_higher Oct. 6 at 1:45 AM
$AGEN Good for Agen? https://www.linkedin.com/posts/ndevitomd_tcl-chris-biggar-and-the-importance-of-nci-activity-7380577295666712576-lnae?utm_medium=ios_app&rcm=ACoAAEHAee4BR-loExEE38VAh_pzlu_m6nyixzY&utm_source=social_share_send&utm_campaign=mail
1 · Reply
joechuck71
joechuck71 Oct. 6 at 12:40 AM
$AGEN Botensilimab + Balstilimab vs Best Supportive Care has moved into phase 3 on the agenus page.
0 · Reply
2_logs_higher
2_logs_higher Oct. 5 at 12:40 AM
$AGEN Doors closing on other opportunities for Agen as they sit in the shoulder of the road broken down waiting on THE ROAD TAKEN An FDA approval is setting a new benchmark for future treatment for first-line small cell lung cancer. The FDA has greenlighted Jazz Pharmaceuticals’ Zepzelca, used in combination with Roche’s Tecentriq, as a first-line maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC), the agency said Thursday. The approval also applies to Tecentriq Hybreza, a subcutaneous version of the Roche PD-L1 inhibitor. https://www.fiercepharma.com/pharma/fda-approval-jazz-and-roche-combo-sets-new-bar-first-line-small-cell-lung-cancer G will come out with a teaser in 2-4 months with 1 patient or mice and say BOT + BAL + a dab of QS-21 is SIGNIFICANTLY superior, no PR, no Wed meeting.
2 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 4 at 9:47 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $AGEN Current Share Price: $4.14 Contracts: $AGEN January 15, 2027 $5 Calls Scale in: $1.06- $1.29 Scale out: $1.64-$2.11 Can Easily Capture: 60% ROI Blended DTE: 469 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
robbiekuss1
robbiekuss1 Oct. 4 at 8:37 PM
$AGEN Is the SaponiQX output considered a generic? SaponiQx, a subsidiary of Agenus, develops and manufactures its saponin-based adjuvants using a proprietary cultured plant cell (cpc) technology. While the headquarters for SaponiQx (and its parent company, Agenus) is in Lexington, Massachusetts, the specific location of its manufacturing is related to Agenus's broader manufacturing operations: Agenus's California Facilities: Agenus had cGMP (current Good Manufacturing Practice) facilities in Berkeley, CA (clinical scale) and Emeryville, CA (commercial scale).
2 · Reply
dikbukiss
dikbukiss Oct. 4 at 8:09 PM
$AGEN nice curl on the 1 month. 3 white soldiers pattern
2 · Reply
BOUDIN420
BOUDIN420 Oct. 3 at 9:52 PM
$AGEN 👇🎯
0 · Reply
robbiekuss1
robbiekuss1 Oct. 3 at 9:15 PM
$AGEN https://firstwordpharma.com/story/6279227 Implications? Opportunities? I will put my money on Garo.
3 · Reply
Biotechguy21
Biotechguy21 Oct. 3 at 8:39 PM
$AGEN pos fooled you again 😂😂😂😂🤡🤡🤡🤡
0 · Reply
2_logs_higher
2_logs_higher Oct. 3 at 8:27 PM
$AGEN Form 4 BOD - Wright Timothy https://d18rn0p25nwr6d.cloudfront.net/CIK-0001098972/dc6fe9cf-8f3e-4988-8361-1314601b19f3.pdf
0 · Reply
2_logs_higher
2_logs_higher Oct. 3 at 8:26 PM
$AGEN Form 4 BOD - HARRISON THOMAS L https://d18rn0p25nwr6d.cloudfront.net/CIK-0001098972/065089ab-acd0-4748-9095-9d81baa9b83d.pdf
1 · Reply
BOUDIN420
BOUDIN420 Oct. 3 at 3:19 PM
$AGEN we are still on the appetizer. Bring on the lunch menu...
0 · Reply
2_logs_higher
2_logs_higher Oct. 3 at 3:15 PM
$AGEN Dr. Kasi in action for COH & CRC patients, but not so much for Agenus anymore. Why?
1 · Reply
manny11419
manny11419 Oct. 3 at 1:31 PM
$AGEN Following catalysts for remainder of the year.(possible SP moving) 1. Survival trends at Esmo 2. Partnership for Ex N/A. 3. Sale of land Vacaville 4. Closing of Zydus transaction 5. Launching of P3 6. Second trip to EMA. 7. Mink to present more data on Gastric
0 · Reply
2_logs_higher
2_logs_higher Oct. 3 at 12:29 PM
$AGEN Garo, Zack, IR, Communications has been asked the following questions: 1. Is Gov shut down likely to affect Zydus deal? 2. NIH shut down, how will trials be updated? Response: crickets
1 · Reply
BOUDIN420
BOUDIN420 Oct. 2 at 3:38 PM
$AGEN keep feeding us bears ty
0 · Reply
Moon37
Moon37 Oct. 2 at 1:08 PM
$AGEN We know you had offer Garo you just didn’t think they were enough. So don’t play coy slimey brother
1 · Reply
Moon37
Moon37 Oct. 2 at 1:06 PM
$AGEN fuck you Garo. fuck you man
1 · Reply